Heron Therapeutics, Inc. (HRTX) - NASDAQ
  • Thu, May 5, 5:28 PM
    | Thu, May 5, 5:28 PM | 1 Comment
  • Fri, Feb. 19, 9:33 AM
    • Heron Therapeutics (HRTX -0.08%) Q4 results: Revenues: $0; R&D Expense: $16.3M (+14.8%); SG&A: $14.8M (+179.2%); Operating Loss: ($31.1M) (-59.5%); Net Loss: ($31.2M) (-51.5%); Loss Per Share: ($0.87) (-22.5%).
    • FY2015 results: Revenues: $0; R&D Expense: $61.2M (+11.7%); SG&A: $35.7M (+81.2%); Operating Loss: ($96.9M) (-29.9%); Net Loss: ($97.6M) (-27.7%); Loss Per Share: ($2.95) (-2.8%); Quick Assets: $131.2M (+80.5%).
    • No guidance given.
    | Fri, Feb. 19, 9:33 AM
  • Fri, Feb. 19, 8:16 AM
    | Fri, Feb. 19, 8:16 AM
  • Nov. 6, 2015, 10:18 AM
    • Heron Therapeutics (HRTX -9%) Q3 results: Revenues: $0; R&D Expense: $14.2M (-3.4%); SG&A: $8.3M (+97.6%); Operating Loss: ($22.5M) (-18.4%); Net Loss: ($22.7M) (-18.2%); Loss Per Share: ($0.63) (+4.5%); Quick Assets: $153M (+110.5%).
    • No guidance given.
    | Nov. 6, 2015, 10:18 AM
  • Nov. 6, 2015, 8:17 AM
    • Heron Therapeutics (NASDAQ:HRTX): Q3 EPS of -$0.63 beats by $0.04
    | Nov. 6, 2015, 8:17 AM
  • Oct. 12, 2015, 12:45 PM
    | Oct. 12, 2015, 12:45 PM
  • Aug. 7, 2015, 8:10 AM
    • Heron Therapeutics (NASDAQ:HRTX): Q2 EPS of -$0.74 misses by $0.09.
    | Aug. 7, 2015, 8:10 AM
  • May 8, 2015, 8:25 AM
    • Heron Therapeutics (NASDAQ:HRTX): Q1 EPS of -$0.70 misses by $0.02.
    | May 8, 2015, 8:25 AM
  • Mar. 13, 2015, 9:56 AM
    • Heron Therapeutics (HRTX +1.1%) Q4 results: Revenues: $0; R&D Expense: $14.2M (+67.1%); SG&A: $5.3M (+0.2%); Operating Loss: ($19.5M) (-41.3%); Net Loss: ($20.6M) (-47.1%); Loss Per Share: ($0.71) (+5.3%).
    • FY2014 results: Revenues: $0; R&D Expense: $54.8M (+68.6%); SG&A: $19.7M (-10.0%); Operating Loss: ($74.6M) (-36.9%); Net Loss: ($76.4M) (-38.2%); Loss Per Share: ($2.87) (+16.1%); Quick Assets: $72.7M (+0.6%).
    • No guidance given.
    | Mar. 13, 2015, 9:56 AM
  • Mar. 13, 2015, 8:17 AM
    • Heron Therapeutics (NASDAQ:HRTX): Q4 EPS of -$0.71 beats by $0.08.
    | Mar. 13, 2015, 8:17 AM
  • Aug. 4, 2014, 10:38 AM
    • Heron Therapeutics (HRTX -1.1%) Q2 results: Revenue: $0; Operating Expenses: $18.8M (+23.7%); Operating Loss: ($18.8M) (-23.7%); Net Loss: ($19.0M) (-23.4%); Loss Per Share: ($0.78) (+22.8%); Quick Assets: $105.0M (+45.2%).
    • No guidance given.
    | Aug. 4, 2014, 10:38 AM
  • Aug. 4, 2014, 8:07 AM
    • Heron Therapeutics (NASDAQ:HRTX): Q2 EPS of -$0.78 misses by $0.04.
    | Aug. 4, 2014, 8:07 AM
  • May 8, 2014, 9:33 AM
    • Heron Therapeutics (HRTX): Q1 EPS of -$0.74 misses by $0.07.
    | May 8, 2014, 9:33 AM
  • Mar. 5, 2014, 8:19 AM
    • Heron Therapeutics (HRTX): Q4 EPS of -$0.75.
    | Mar. 5, 2014, 8:19 AM
Company Description
Heron Therapeutics, Inc. is a pharmaceutical company. It designs and commercializes of polymer technologies for pharmaceutical and other applications. The company develops products using its proprietary Biochronomer polymer based drug delivery technology. Its primary focus is on its product... More
Sector: Healthcare
Industry: Drug Manufacturers - Major
Country: United States